Related Experiment Video
Updated: Aug 14, 2025

08:14
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
15.7K
The promise and harms of screening for plasma cell dyscrasias
Ghulam Rehman Mohyuddin1, Rajshekhar Chakraborty2, Edward R Scheffer Cliff3
1Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
British Journal of Haematology
|January 10, 2023
Abstract:
In this perspective, we highlight both the promise and harms of screening for plasma cell dyscrasias, as well as the implications of the use of mass spectrometry for diagnosing monoclonal gammopathy of undetermined significance in routine practice.

